TScan Therapeutics, Inc. (TCRX) reported Q4 EPS of ($0.78), $0.06 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $4.1 million.
TScan Therapeutics, Inc. (TCRX) reported Q4 EPS of ($0.78), $0.06 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $4.1 million.